早期HER2阳性乳腺癌的辅助性帕妥珠单抗和曲妥珠单抗治疗 - Suppr | 超能文献

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

出版信息

N Engl J Med. 2017 Aug 17;377(7):702. doi: 10.1056/NEJMx170011. Epub 2017 Jul 12.

DOI:10.1056/NEJMx170011

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.早期HER2阳性乳腺癌的辅助性帕妥珠单抗和曲妥珠单抗治疗

N Engl J Med. 2017 Aug 17;377(7):702. doi: 10.1056/NEJMx170011. Epub 2017 Jul 12.

2

Pertuzumab in HER2-positive breast cancer.曲妥珠单抗治疗人表皮生长因子受体 2 阳性乳腺癌。

Curr Med Res Opin. 2012 Oct;28(10):1709-16. doi: 10.1185/03007995.2012.728132. Epub 2012 Oct 11.

3

Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.人表皮生长因子受体2阳性早期女性乳腺癌的全身靶向治疗：对2014年安大略癌症护理全身治疗指南证据的系统评价

Curr Oncol. 2015 Mar;22(Suppl 1):S114-22. doi: 10.3747/co.22.2322.

4

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.新辅助帕妥珠单抗和曲妥珠单抗治疗局部晚期、炎症型或早期 HER2 阳性乳腺癌的疗效和安全性（NeoSphere）：一项随机、多中心、开放性、Ⅱ期临床试验。

Lancet Oncol. 2012 Jan;13(1):25-32. doi: 10.1016/S1470-2045(11)70336-9. Epub 2011 Dec 6.

5

Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.曲妥珠单抗在治疗 HER2 阳性转移性乳腺癌中的应用。

Adv Ther. 2013 Jul;30(7):645-58. doi: 10.1007/s12325-013-0043-2. Epub 2013 Jul 24.

6

Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.帕妥珠单抗联合曲妥珠单抗和多西他赛用于HER2阳性转移性乳腺癌。

Expert Rev Anticancer Ther. 2015 Jan;15(1):17-26. doi: 10.1586/14737140.2015.992418. Epub 2014 Dec 12.

7

Pertuzumab: a new targeted therapy for HER2-positive metastatic breast cancer.帕妥珠单抗：一种用于治疗 HER2 阳性转移性乳腺癌的新型靶向治疗药物。

Pharmacotherapy. 2014 Jan;34(1):60-71. doi: 10.1002/phar.1338. Epub 2013 Aug 5.

8

Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.紫杉醇联合曲妥珠单抗和帕妥珠单抗治疗HER2阳性转移性乳腺癌患者的心脏安全性

Oncologist. 2016 Apr;21(4):418-24. doi: 10.1634/theoncologist.2015-0321. Epub 2016 Mar 16.

9

Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.2015年HER2阳性乳腺癌患者的最佳辅助治疗

Breast. 2015 Nov;24 Suppl 2:S143-8. doi: 10.1016/j.breast.2015.07.034. Epub 2015 Aug 5.

10

Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.使用111铟-二乙三胺五乙酸-帕妥珠单抗的微型单光子发射计算机断层扫描/计算机断层扫描（Micro-SPECT/CT）能灵敏地检测携带MDA-MB-361人乳腺癌异种移植瘤的无胸腺小鼠中曲妥珠单抗介导的HER2下调和肿瘤反应。

J Nucl Med. 2009 Aug;50(8):1340-8. doi: 10.2967/jnumed.109.062224. Epub 2009 Jul 17.

引用本文的文献

1

Exploring the frontiers: a panoramic analysis of global multi-specific antibody clinical trials.探索前沿：全球多特异性抗体临床试验全景分析

Int J Surg. 2025 May 1;111(5):3641-3645. doi: 10.1097/JS9.0000000000002329.

2

Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer.22 例晚期乳腺癌患者 HER2 突变和 HER2 融合的临床特征和治疗结局。

Thorac Cancer. 2023 Dec;14(34):3381-3388. doi: 10.1111/1759-7714.15130. Epub 2023 Oct 20.

3

Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer.靶向混杂二聚化克服了乳腺癌中 ERBB2 二聚化抑制剂的固有耐药性。

Breast Cancer Res. 2019 Mar 21;21(1):43. doi: 10.1186/s13058-019-1127-y.